Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RA-18C3 · 2 trials · 2 indications
Incidence and type of adverse clinical events
| Arm | Type | Description |
|---|---|---|
| RA-18C3 | EXPERIMENTAL | - |
| Single group | OTHER | - |
| Name | Type | Description |
|---|---|---|
| RA-18C3 | DRUG | For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection. For subjects weighing \> 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection. |
Inclusion Criteria: 1. Age: ≥ 18 2. Moderate to moderately severe inflammatory acne vulgaris: * Investigator's Global Assessment grade of ≥ 3 and, * ≥ 15 inflammatory lesions (no more than 6 nodules) and, * ≥ 15 non-inflammatory lesions 3. Four week washout period for topical and oral ant...
RA-18C3 is an investigational small molecule being developed for dermatology conditions, specifically moderate to severe psoriasis and moderate to severe acne vulgaris. It is currently in Phase 2 clinical development and has not been approved by the FDA.
RA-18C3 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is in Phase 2 clinical trials for dermatology indications.
RA-18C3 is in Phase 2 clinical development. It has completed two Phase 2 trials, one for psoriasis and one for acne vulgaris, but it remains investigational and is not yet approved for any use.
RA-18C3 has completed two Phase 2 trials. NCT01384630 evaluated safety, pharmacokinetics, and efficacy in 8 subjects with moderate to severe psoriasis. NCT01474798 evaluated the drug in 11 subjects with moderate to severe acne vulgaris. Both trials were conducted in the United States.
No alternative names for RA-18C3 have been reported. The drug is identified solely by its code name RA-18C3 in clinical trial registries and development records.